Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Aedes aegypti - mosquito vector of zika, chikungunya and rift valley fever.

Outbreak Pathogens: Zika, Chikungunya, Rift Valley Fever and MERS

The vulnerability of the world to infectious disease, highlighted by the 2014 Ebola virus disease outbreak in West Africa, has led to major discussions between many authorities and expert groups regarding which vaccines to develop in order to avoid more outbreaks. The World Health Organisation, the UK Vaccines Research and Development Network, the recently formed Coalition for Epidemic Preparedness Innovations, and Science Magazine have all developed priority lists of target diseases for vaccine design and development.

Common to these lists are ten diseases, all of which the Jenner Institute is developing candidate vaccines for, using its proprietary simian adenoviral vectors and the specialist expertise of its viral vector core facility.

Four of these vectored vaccine candidates will now be progressing rapidly to GMP manufacture and clinical trials with UK government funding support, as described here:

Zika Virus Vaccine Programme

Chikungunya Virus Vaccine Programme

Rift Valley Fever Vaccine Programme

MERS Vaccine Programme